Search results
Results from the WOW.Com Content Network
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [4]
As of 2007, ABVD is widely used as the initial chemotherapy treatment for newly diagnosed Hodgkin lymphoma. [citation needed] It has been the most effective and least toxic chemotherapy regimen available for treating early-stage Hodgkin Lymphoma. [1]
Stanford V (usually spoken as Stanford Five), is a chemotherapy regimen (with accompanying Radiation therapy) intended as a first-line treatment for Hodgkin lymphoma.The regimen was developed in 1988, with the objective of maintaining a high remission rate while reducing the incidence of acute and long term toxicity, pulmonary damage, and sterility observed in alternative treatment regimens ...
Days 1–4 Prednisolone: 60 mg/m 2: By mouth, twice a day (PO BID) Days 1–5 Oncovin: vincristine: 0.4 mg/m 2: IV continuous infusion over 24 h: Days 1–4 Cyclophosphamide: 750 mg/m 2: IV bolus given over 15 min: Day 5 Hydroxydaunorubicin: doxorubicin: 10 mg/m 2: IV continuous infusion over 24 h: Days 1–4
ICE in the context of chemotherapy is an acronym for one of the chemotherapy regimens, used in salvage treatment of relapsed or refractory non-Hodgkin's lymphoma and Hodgkin lymphoma. In case of CD20-positive B cell lymphoid malignancies the ICE regimen is often combined today with rituximab. This regimen is then called ICE-R or R-ICE or RICE.
However, research shows that certain chemotherapy drugs can, under specific conditions, boost the immune response against tumors and enhance the effectiveness of immunotherapy. [ 6 ] Chemotherapy can boost tumor immunity in two main ways: (a) by killing cancer cells through immunogenic cell death , and (b) by affecting both cancerous and normal ...
Dacarbazine, also known as imidazole carboxamide and sold under the brand name DTIC-Dome, is a chemotherapy medication used in the treatment of melanoma and Hodgkin's lymphoma. [3] For Hodgkin's lymphoma it is often used together with vinblastine, bleomycin, and doxorubicin. [3] It is given by injection into a vein. [3]
It was established as Clinical Lymphoma in 2000, renamed to Clinical Lymphoma & Myeloma in 2005 and obtained its current name in 2010. The journal covers research on detection, diagnosis, prevention, and treatment of lymphoma, myeloma, leukemia, and related disorders, including macroglobulinemia, amyloidosis, and plasma-cell dyscrasias.